Compare · RVMD vs ZURA
RVMD vs ZURA
Side-by-side comparison of Revolution Medicines Inc. (RVMD) and Zura Bio Limited (ZURA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVMD and ZURA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $36.09B, about 89.2x ZURA ($404.7M).
- Over the past year, RVMD is up 341.9% and ZURA is up 262.8% - RVMD leads by 79.1 points.
- RVMD has been more active in the news (23 items in the past 4 weeks vs 9 for ZURA).
- RVMD has more recent analyst coverage (25 ratings vs 9 for ZURA).
- Company
- Revolution Medicines Inc.
- Zura Bio Limited
- Price
- $169.73+0.14%
- $4.25-1.51%
- Market cap
- $36.09B
- $404.7M
- 1M return
- +12.01%
- -2.64%
- 1Y return
- +341.89%
- +262.82%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 23
- 9
- Recent ratings
- 25
- 9
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest RVMD
- Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Kim Lorence H. was granted 1,191 shares, increasing direct ownership by 2% to 74,281 units (SEC Form 4)
- Director Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)
- Director Anderson Elizabeth M was granted 1,191 shares, increasing direct ownership by 14% to 9,406 units (SEC Form 4)
- Director Horning Sandra was granted 1,191 shares, increasing direct ownership by 1% to 97,765 units (SEC Form 4)
- Director Clyburn Frank was granted 1,191 shares, increasing direct ownership by 12% to 10,929 units (SEC Form 4)
- Director Patel Sushil was granted 1,191 shares, increasing direct ownership by 5% to 24,281 units (SEC Form 4)
- Director Borellini Flavia was granted 1,191 shares, increasing direct ownership by 5% to 26,215 units (SEC Form 4)
- Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
- SEC Form 8-K filed by Revolution Medicines Inc.
Latest ZURA
- New insider Mathew Marlyn Teresa claimed ownership of 129,182 units of Class A Ordinary Shares (SEC Form 3)
- SEC Form 4 filed by Director Jarrett Jennifer
- SEC Form 4 filed by Director Thiara Parvinder
- SEC Form 4 filed by Director Schoch Steven J
- SEC Form 4 filed by Director Nirula Ajay
- SEC Form 4 filed by Director Eisner Mark
- SEC Form 4 filed by Director Munshi Amit
- SEC Form 4 filed by Director Becker Daniel J.
- Zura Bio Limited filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Zura Bio Limited